Alnylam Reports Positive Phase II Data on TTR Drug, Aims for Phase III by Year End | GenomeWeb

Alnylam Pharmaceuticals this week announced positive clinical results from an ongoing phase II trial of ALN-TTR02, an investigational treatment for TTR-mediated amyloidosis, reporting that the drug was able to knock down levels of the protein that causes the disease by as much as 93 percent.

The gene inhibition was rapid, dose-dependent, and durable, Alnylam said. Additionally, ALN-TTR02 was generally safe and well tolerated in the trial — all of which puts the company on track to move into phase III before the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.